No dual-labeled tracers, which enable both fluorescence visualization, and radioactivity-based depth of detection are FDA-approved and those in clinical trials target carbonic anhydrase IX, gastrin-releasing peptide receptor, and CEA, which are not as uniformly and highly expressed in neuroblastoma [17, 19, 43, 44]. This evidence concerns the gene CEACAM5 and neuroblastoma.